Subtopic Deep Dive
Urotensin II in Renal Function
Research Guide
What is Urotensin II in Renal Function?
Urotensin II in renal function examines the peptide's vasoconstrictive effects on glomerular filtration and sodium handling, particularly its elevated levels and role in diabetic nephropathy and chronic kidney disease.
Urotensin II (U-II) acts via its receptor GPR14/UT, influencing renal hemodynamics and sodium excretion. Studies show increased urinary U-II excretion in type 2 diabetes patients correlates with nephropathy progression (Totsune et al., 2004, 98 citations). Over 10 papers from the list link U-II to oxidative stress and hypertension impacting kidneys.
Why It Matters
U-II's activation of NADPH oxidase in vascular cells promotes oxidative stress, contributing to renal damage in hypertension and diabetes (Djordjevic et al., 2004, 162 citations; Totsune et al., 2004). Elevated plasma and urinary U-II levels associate with diabetic nephropathy progression, suggesting diagnostic and therapeutic targets (Totsune et al., 2004). This informs renoprotective strategies in cardiometabolic syndrome, as U-II modulates vasoconstriction across species (Douglas et al., 2000, 227 citations).
Key Research Challenges
Species-variable vasoconstriction
Human U-II shows potent vasoconstriction in some species like monkey but weak effects in rats and mice (Douglas et al., 2000, 227 citations). This variability complicates renal function models. Translating findings to human kidneys remains difficult.
Linking U-II to nephropathy progression
Elevated U-II in type 2 diabetes correlates with urinary excretion and nephropathy but causal mechanisms need clarification (Totsune et al., 2004, 98 citations). Oxidative stress pathways overlap with hypertension (Rodrigo et al., 2011, 427 citations). Longitudinal studies are limited.
Oxidative stress integration
U-II activates NADPH oxidase, generating renal oxidative stress, but interactions with isoprostanes and hypertension pathways are underexplored (Djordjevic et al., 2004, 162 citations; Bauer et al., 2014, 147 citations). Quantifying contributions in glomerular filtration is challenging. Receptor-specific inhibitors lack testing.
Essential Papers
The role of oxidative stress in the pathophysiology of hypertension
Ramón Rodrigo, Jaime González, Fabio Paoletto · 2011 · Hypertension Research · 427 citations
Differential vasoconstrictor activity of human urotensin‐II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey
Stephen A. Douglas, Anthony C. Sulpizio, Valerie Piercy et al. · 2000 · British Journal of Pharmacology · 227 citations
Urotensin‐II (U‐II) and its G‐protein‐coupled receptor, GPR14, are expressed within mammalian cardiac and peripheral vascular tissue and, as such, may regulate mammalian cardiovascular function. Th...
Essential hypertension and oxidative stress: New insights
Jaime González · 2014 · World Journal of Cardiology · 194 citations
Essential hypertension is a highly prevalent pathological condition that is considered as one of the most relevant cardiovascular risk factors and is an important cause of morbidity and mortality a...
Human Urotensin II Is a Novel Activator of NADPH Oxidase in Human Pulmonary Artery Smooth Muscle Cells
Talija Djordjevic, Rachida S. BelAiba, Steve Bonello et al. · 2004 · Arteriosclerosis Thrombosis and Vascular Biology · 162 citations
Background— Human urotensin II (hU-II) is a potent vasoactive peptide possibly involved in pulmonary hypertension. Because the signaling mechanisms activated by this peptide in the pulmonary vascul...
Primary Aldosteronism: Changing Definitions and New Concepts of Physiology and Pathophysiology Both Inside and Outside the Kidney
Michael Stowasser, Richard D. Gordon · 2016 · Physiological Reviews · 147 citations
In the 60 years that have passed since the discovery of the mineralocorticoid hormone aldosterone, much has been learned about its synthesis (both adrenal and extra-adrenal), regulation (by renin-a...
Pathophysiology of isoprostanes in the cardiovascular system: implications of isoprostane‐mediated thromboxane<scp>A</scp><sub>2</sub>receptor activation
Jochen Bauer, Anne Ripperger, Stefan Frantz et al. · 2014 · British Journal of Pharmacology · 147 citations
Isoprostanes are free radical‐catalysed PG ‐like products of unsaturated fatty acids, such as arachidonic acid, which are widely recognized as reliable markers of systemic lipid peroxidation and ox...
Is urotensin‐II the new endothelin?
Janet J. Maguire, Anthony P. Davenport · 2002 · British Journal of Pharmacology · 130 citations
Urotensin‐II (U‐II), a peptide isolated from the urophysis of teleost fish 35 years ago, is the endogenous ligand of the mammalian orphan receptor GPR14/SENR. Recently, human homologues of both the...
Reading Guide
Foundational Papers
Start with Douglas et al. (2000, 227 citations) for U-II vasoconstrictor profile across species, essential for renal hemodynamics; Totsune et al. (2004, 98 citations) for clinical urinary excretion in diabetes; Djordjevic et al. (2004, 162 citations) for NADPH oxidase mechanism linking to oxidative renal stress.
Recent Advances
Vaudry et al. (2014, 100 citations) structures U-II receptor functions; González (2014, 194 citations) updates hypertension oxidative stress relevant to renal U-II; Bauer et al. (2014, 147 citations) on isoprostanes in cardiovascular paths overlapping kidney effects.
Core Methods
Core methods: species-isolated vascular ring assays (Douglas et al., 2000); plasma/urine RIA immunoassays (Totsune et al., 2004); NADPH oxidase activity assays and siRNA knockdown in smooth muscle cells (Djordjevic et al., 2004); receptor binding and function reviews (Vaudry et al., 2014).
How PapersFlow Helps You Research Urotensin II in Renal Function
Discover & Search
Research Agent uses searchPapers and exaSearch to find U-II renal papers like Totsune et al. (2004) on diabetic nephropathy excretion. citationGraph reveals connections from Douglas et al. (2000) vasoconstriction to oxidative stress works. findSimilarPapers expands from Vaudry et al. (2014) review to species-specific renal effects.
Analyze & Verify
Analysis Agent applies readPaperContent to extract U-II excretion data from Totsune et al. (2004), then verifyResponse with CoVe checks claims against Rodrigo et al. (2011) hypertension stress. runPythonAnalysis performs statistical verification on citation networks or NADPH activation metrics from Djordjevic et al. (2004), graded by GRADE for evidence strength in renal vasoconstriction.
Synthesize & Write
Synthesis Agent detects gaps in U-II renal causality beyond correlations (Totsune et al., 2004), flags contradictions in species vasoconstriction (Douglas et al., 2000). Writing Agent uses latexEditText and latexSyncCitations to draft reviews citing 10+ papers, latexCompile generates figures, exportMermaid diagrams U-II/GPR14 pathways.
Use Cases
"Analyze correlation stats between urinary U-II levels and diabetic nephropathy progression from Totsune 2004."
Research Agent → searchPapers → Analysis Agent → readPaperContent + runPythonAnalysis (pandas correlation plot) → matplotlib output with statistical p-values.
"Draft LaTeX review on U-II vasoconstriction in renal hypertension citing Douglas 2000 and Rodrigo 2011."
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations + latexCompile → compiled PDF with synced bibliography.
"Find code for U-II NADPH oxidase simulations from Djordjevic 2004 related papers."
Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → verified simulation scripts for oxidative stress modeling.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on U-II renal excretion, structures report chaining Totsune et al. (2004) to Vaudry et al. (2014) receptor functions with GRADE grading. DeepScan's 7-step analysis verifies oxidative links (Djordjevic et al., 2004) using CoVe checkpoints and runPythonAnalysis for data plots. Theorizer generates hypotheses on U-II antagonists for CKD from Douglas et al. (2000) vasoconstriction variances.
Frequently Asked Questions
What is the definition of Urotensin II in renal function?
Urotensin II in renal function studies the peptide's effects on glomerular filtration, sodium handling, and its elevation in diabetic nephropathy via GPR14 receptor (Totsune et al., 2004).
What methods study U-II renal effects?
Methods include plasma/urinary immunoassays for levels (Totsune et al., 2004), isolated vessel vasoconstriction assays across species (Douglas et al., 2000), and NADPH oxidase activation in smooth muscle cells (Djordjevic et al., 2004).
What are key papers on this subtopic?
Key papers: Totsune et al. (2004, 98 citations) on U-II in diabetic nephropathy; Douglas et al. (2000, 227 citations) on species vasoconstriction; Djordjevic et al. (2004, 162 citations) on NADPH oxidase; Vaudry et al. (2014, 100 citations) receptor review.
What open problems exist?
Open problems: causal role of U-II in CKD progression beyond correlations (Totsune et al., 2004); species translation for human renal models (Douglas et al., 2000); U-II-specific antagonists for oxidative stress in hypertension (Rodrigo et al., 2011).
Research Cardiovascular, Neuropeptides, and Oxidative Stress Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Urotensin II in Renal Function with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers